Treatment Switching

Managing Trial Data When Patients Switch Treatment Groups

Although allowing patients in the control group of a clinical trial to switch onto the experimental treatment is a common occurrence in oncology drug trials, it can present significant challenges for the accurate interpretation of trial findings when a substantial number of patients switch treatments. GPC researched how to manage treatment switching in the design and analysis of oncology drug trials, to help ensure that the trial results are meaningful and appropriately construed.

Development of Best Practices

View Process

Best Practices

We developed a guidance document that provides best practice recommendations to ensure that oncology drug trials can permit such switches and still generate scientifically valid results. It will also provide greater clarity and consistency about the expectations of key decision makers when assessing evidence from trials in which treatment switching has occurred.

The report is available to download in our resource center.